AAU will oversee the design of a platform to aid patients in selecting the best treatment plan for lung cancer

AAU will oversee the design of a platform to aid patients in selecting the best treatment plan for lung cancer

I3LUNG will foster the implementation of artificial intelligence-based personalized medical care for lung cancer patients to improve the outcome of the treatment and reduce costs

I3LUNG is a research initiative that aims to create a cutting-edge decision-making tool to aid both clinicians and patients in selecting the best lung cancer treatment plan, tailored to the specific needs and situation of each individual patient.

This individualized patient selection plan will help reduce the economic burden for patients and, in the longer term, for healthcare systems, and first and foremost it will improve the outcomes of therapy for patients by better matching them and their specific situation to different available treatments.

To accomplish this, the project will use artificial intelligence (AI), in particular deep and machine learning methodologies (DL and ML) to analyze a wide range of information such as baseline clinical features, radiomics, and available biological characteristics of the tumor.

AAU will oversee the design of a novel web-based platform to collect all the available data and the new generated ones as foreseen by the project. The platform will allow the different clinical partners to run the ML/AI algorithms on the collected data and will enable the patients to see their progress.

Moreover, AAU and ML3 will properly standardize the dataset and will prepare a benchmark to be deployed in well-known EU repositories.

All these data will come from the retrospective analysis of 2,000 patients from multiple centers, along with the enrolment of 200 new patients in a prospective study for the generation of new biological multiomic data, such as: tumor mutational burden, immune circulating profiling, digital pathology, gut microbiome, radiomics and other multi-omics approaches.

In parallel, a psychological study will also be conducted and will integrate the aspect of the patients’ experiences and preferences as an input in the development of a co-decision aid tool. Six outstanding clinical cancer centers located from all over the world (Italy, Germany, Greece, Spain, Israel, USA) are involved in these data collection processes.

Aiming to push the standards

The I3LUNG project plans to develop a European - and beyond - platform which will capitalize on these new tools to cope with the complexity of available data on lung cancer biomarkers. By synthesizing and correlating the information from multiple sources of biological and clinical information, it will thereby help in developing a set of methods that will in turn enable the project’s technical partners to construct a novel AI tool which can provide individualized predictions for the efficacy of IO in specific patients, and offer suggestions for care pathways, in coordination with all involved actors (patients, oncologists, researchers) and their human intelligence.

Harnessing the power of AI and ML could change the way cancer is treated and push the standard of care towards a more personalized approach for each individual cancer patient. If successful, the approach presented in I3LUNG could in the near future justify an initial pilot study which could expand on the project and attempt to apply the tools and methodologies developed to all the cancer types for which patients are candidate to IO in daily practice.

This challenging objective will be a collaborative effort, which will include 16 partners in the I3LUNG consortium. Some among the best European and International organizations will join forces for this ambitious project: Fondazione IRCCS Istituto Nazionale dei Tumori (INT, Milan, Italy) is the coordinator of the Consortium with its PI Dr. Arsela Prelaj, Politecnico di Milano (POLIMI, Milan, Italy), Istituto di Ricerche Farmacologiche Mario Negri (IRFMN, Milan, Italy), Istituto Europeo di Oncologia (IEO; Milan, Italy), ML Cube (Milan, Italy), LungenClinic Grosshansdorf GmbH (GHD, Grosshansdorf, Germany), Universitaetsklinikum Hamburg-Eppendorf (UKE, Hamburg, Germany), ), Vall d’Hebron Institute of Oncology (VHIO, Barcelona, Spain), Medica Scientia Innovation Research (MEDSIR, Barcelona, Spain & New Jersey, USA), Metropolitan Hospital (MH, Pireas, Greece), Shaare Zedek Medical Center (SZMC, Jerusalem, Israel), Katholieke Universiteit Leuven (KUL, Leuven, Belgium), Institutet for Halso-OCH Sjukvardsekonomi Aktiebolag (IHE, Lund, Sweden), the University of Chicago (UOC, Chicago, USA), Aalborg Universitet (AAU, Aalborg, Denmark), Lung Cancer Europe (LUCE, Bern, Switzerland).

For further information about the project contact Assoc. Prof. Sokol Kosta (sok@es.aau.dk) or Communications Officer Mads Sejer Nielsen (sejer@es.aau.dk)

All news

See the list